Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of Parkinsonism

Neurobiology of Disease

Volumn 4, Issue 3-4, 1997, Pages 247-253

  Zigmond, Michael J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION;

EID: 0030687682     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1997.0157     Document Type: Article

References (59)

1. Abercrombie E. D., Zigmond M. J. Partial injury to central noradrenergic neurons: reduction of tissue norepinephrine content is greater than reduction of extracellular norepinephrine measured by microdialysis. J. Neurosci. 9:1989;4062-4067.
2. Abercrombie E. D., Bonatz A. E., Zigmond M. J. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine treated rats. Brain Res. 525:1990;36-44.
3. Acheson A. L., Zigmond M. J. Short and long term changes in tyrosine hydroxylase activity in rat brain after subtotal destruction of central noradrenergic neurons. J. Neurosci. 1:1981;493-504.
4. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature. 245:1973;150-151.
5. Altar C. A., Marien M. R., Marshall J. F. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48:1987;390-399.
6. Bernath S., Zigmond M. J. Dopamine may influence striatal GABA release via three separate mechanisms. Brain Res. 476:1989;373-376.
7. Bernheimer H., Hornykiewicz O. Herabgestzte konzentration der homovanillinsäure im gehirn von parkinsonkranken menschen als ausdruck der störung des zentralen dopaminstoffwechsels. Klin. Wochschr. 43:1965;711-715.
8. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seiterberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455.
9. Chiodo L. A., Acheson A. L., Zigmond M. J., Stricker E. M. Subtotal destruction of central noradrenergic projections increases the firing rate of locus coerulleus cells. Brain Res. 264:1983;123-126.
10. 33. Eur. J. Pharmacol. 56:1979;277-281.
11. Cubeddu L. X., Hoffmann I. S. Frequency-dependent release of acetylcholine and dopamine from rabbit striatum: its modulation by dopaminergic receptors. J. Neurochem. 41:1983;94.
12. Cubeddu L. X., Hoffmann I. S., James M. K. Frequency-dependent effects of neuronal uptake inhibitors on the autoreceptor-mediated modulation of dopamine and acetylcholine release from the rabbit striatum. J. Pharmacol. Exp. Ther. 226:1983;88.
13. Fluharty S. J., Rabow L. E., Zigmond M. J., Stricker E. M. Tyrosine hydroxylase activity in the sympathoadrenal system under basal and stressful condition: Effect of 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235:1985;354-360.
14. Garris P. A., Walker Q. D., Wightman R. M. Decreases in dopamine release and uptake rates in the partially denervated striatum are proportional to the loss of dopamine terminals. Soc. Neurosci. Abstr. 21:1995;1245.
15. 12. Neuroscience. 19:1986;1109-1117.
16. Grewaal D., Fibiger H., McGeer E. 6-Hydroxydopamine and striatal acetylcholine levels. Brain Res. 73:1974;372-375.
17. Guyenet P., Agid Y., Javoy F., Beaujouan J., Rossier J., Glowinski J. Effects of dopaminergic receptor agonists and antagonists on the activity of the neo-striatal cholinergic system. Brain Res. 84:1975;227-244.
18. Harsing L. G. Jr., Zigmond M. J. Dopaminergic inhibition of striatal GABA release after 6-hydroxydopamine. Brain Res. 738:1997a;142-145.
19. Harsing L. G. Jr., Zigmond M. J. Influence of dopamine on GABA release in striatum: Evidence for D1-D2 interactions and non-synaptic influences. Neuroscience. 77:1997b;419-429.
20. Hefti F., Melamed E., Wurtman R. J. Partial lesions of the dopaminergic nigrostriatal system in the brain: Biochemical characterization. Brain Res. 195:1980;95-122.
21. Hertting G., Zumstein A., Jackisch R., Hoffman I., Starke K. Modulation by endogenous dopamine of the release of acetylcholine in the caudate nucleus of the rabbit. Naunyn-Schmiedeberg's Arch. Pharmacol. 315:1980;111.
22. Hollerman J. R., Grace A. A. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res. 533:1990;203-212.
23. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:1966;925-964.
24. D. Jackson, 1990, Dopaminergic Inhibition of Striatal Acetylcholine Release: The Impact of 6-Hydroxydopamine,L, University of Pittsburgh, Pittsburgh.
25. Liang L. P., Jiang D. H. The effect of 6-hydroxydopamine on the levels of catecholamines, lipid peroxidation, and antioxidant enzymes in rat brain. J. Neurol. Psychiatry. 24:1991;223-227.
26. Mackenzie R. G., Stachowiak M. K., Zigmond M. J. Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine. Eur. J. Pharmacol. 168:1989;43-52.
27. Marshall J. F., Teitelbaum P. A comparison of the eating in response to hypothermic and glucoprivic challenges after nigral 6-hydroxydopamine and lateral hypothalamic electrolytic lesions in rats. Brain Res. 55:1973;229-233.
28. Moore R. Y., Zigmond M. J. Compensatory mechanisms in central neurodegenerative disease. Neurodegenerative Diseases. 1994;Saunders, Philadelphia. p. 355-369.
29. Nisenbaum E. S., Stricker E. M., Zigmond M. J., Berger T. W. Long-term effects of dopamine-depleting brain lesions on spontaneous activity of Type II striatal neurons: Relation to behavioral recovery. Brain Res. 398:1986;221-230.
30. Nisenbaum E. S., Stricker E. M., Zigmond M. J., Berger T. W. Spontaneous activity of Type II but not Type I striatal neurons is correlated with recovery of behavioral function after dopamine-depleting brain lesions. Brain Res. 473:1988;389-393.
31. Nisenbaum L. K., Kitai S. T., Crowley W. R., Gerfen C. R. Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion. Neuroscience. 60:1994;927-937.
32. Onn S. P., Berger T. W., Stricker E. M., Zigmond M. J. Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: Histochemical and neurochemical analysis. Brain Res. 376:1986;8-19.
33. Orr W. B., Gardiner T. W., Stricker E. M., Zigmond M. J., Berger T. W. Short-term effects of dopamine-depleting brain lesions on spontaneous activity of striatal neurons: Relation to local dopamine concentration and behavior. Brain Res. 376:1986;20-28.
34. Richardson I. W., Szerb J. C. The release of labelled acetylcholine and choline from cerebral cortical slices stimulated electrically. Br. J. Pharmacol. 52:1974;499-507.
35. Robinson T. E., Whishaw I. Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450:1988;209-224.
36. Sherman T. G., Moody C. A. Alterations in tyrosine hydroxylase expression following partial lesions of the nigrostriatal bundle. Mol. Brain Res. 29:1995;285-296.
37. Sivam S. P., Breese G. R., Napier T. C., Mueller R. A., Hong J. S. Dopaminergic regulation of proenkephalin-A gene expression in the basal ganglia. NIDA Res. Monogr. 75:1986;389-392.
38. Snyder A. M., Stricker E. M., Zigmond M. J. Stress-induced neurological impairments in an animal model of parkinsonism. Ann. Neurol. 18:1985;544-551.
39. Snyder G. L., Keller R. W. Jr., Zigmond M. J. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: Evidence for compensatory hyperactivity of residual terminals. J. Pharmacol. Exp. Ther. 253:1990;867-876.
40. Somogyi G. T., Szerb J. C. Demonstration of acetylcholine release by measuring overflow of labelled choline from cerebral cortical slices. J. Neurochem. 19:1972;2667-2677.
41. Stachowiak M. K., Stricker E. M., Jacoby J. H., Zigmond M. J. Increased tryptophan hydroxylase activity in serotonergic nerve terminals spared by 5,7-dihydroxytryptamine. Biochem. Pharmacol. 35:1986;1241-1248.
42. Stachowiak M. K., Keller R. W. Jr., Stricker E. M., Zigmond M. J. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 7:1987;1648-1654.
43. Starke K., Reimann W., Zumstein A., Hertting G. Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 305:1978;27-36.
44. Staunton D. A., Wolff B. B., Groves P. M., Molinoff P. B. Dopamine receptor changes following destruction of the nigrostriatal pathway: Lack of a relationship to rotational behavior. Brain Res. 211:1981;315-327.
45. Stricker E. M., Zigmond M. J. Effects on homeostasis of intraventricular injections of 6-hydroxydopamine in rats. J. Comp. Physiol. Psychol. 86:1974;973-994.
46. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;95-122.
47. Voorn P., Roest G., Groenewegen H. J. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
48. Young W. S. III, Bonner T. I., Brann M. R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
49. Zhang W. Q., Tilson H. A., Nanry K. P., Hudson P. M., Hong J. S., Stachowiak M. K. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res. 461:1988;335-342.
50. Zigmond M. J. Chemical transmission in the brain: homeostatic regulation and its functional implications. Bloom F. Progress in Brain Research. 1994;115-122 Elsevier.
51. Zigmond M. J., Keefe K. A. 6-Hydroxydopamine as a tool for studying catecholamines in adult animals: lessons from the neostriatum. Kostrzewa R. Highly Selective Neurotoxins: Basic and Clinical Applications. 1997;Humana Press, Clifton.
52. Zigmond M. J., Stricker E. M. Adaptive properties of monoaminergic neurons. Lajtha A. Handbook of Neurochemistry, Alterations of Metabolites in the Nervous System. 1985;87-102 Plenum, New York.
53. Zigmond M. J., Stricker E. M. Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats. Science. 177:1972;1211-1214.
54. Zigmond M. J., Stricker E. M. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science. 182:1973;717-720.
55. Zigmond M. J., Stricker E. M. Behavioral and neurochemical effects of central catecholamine depletion: A possible model for "subclinical" brain damage. Hanin I., Usdin E. Animal Models in Psychiatry and Neurology. 1977;415-429 Pergamon, New York.
56. Zigmond M. J., Stricker E. M. Supersensitivity after intraventricular 6-hydroxydopamine: Relation to dopamine depletion. Experimentia. 36:1980;436-437.
57. Zigmond M. J., Acheson A. L., Stachowiak M. K., Stricker E. M. Neurochemical compensation after nigrostriatal injury in an animal model of preclinical Parkinsonism. Arch. Neurol. 41:1984;856-861.
58. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A., Stricker E. M. Compensatory responses to partial loss of dopaminergic neurons: Studies with 6-hydroxydopamine. Schneider J. S., Gupta M. Current Concepts in Parkinson's Disease Research. 1993;99-140 Hogrefe & Huber, Toronto.
59. Zigmond M. J., Castro S. L., Keefe K. A., Abercrombie E. D., Sved A. F. Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Amino Acids. 1997.